Skip to main content

Table 7 Results of scenario analyses

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Scenario Incremental costs Incremental QALYs ICER
Exponential survival function for PFS £17,366 0.62 £27,789
Weibull survival function for PFS £17,055 0.64 £25,499
Log-normal survival function for PFS £15,921 0.77 £18,691
Gamma survival function for PFS £17,193 0.61 £27,318
Gompertz survival function for PFS £17,578 0.59 £30,099
Weibull survival function for PrePS and PPS £16,288 0.72 £20,368
Log-logistic survival function for PrePS and PPS £16,240 0.57 £22,284
Log-normal survival function for PrePS and PPS £16,256 0.47 £23,700
Gamma survival function for PrePS and PPS £16,332 0.81 £19,489
Gompertz survival function for PrePS and PPS £16,127 0.75 £19,905
Equal PrePS across arms £16,015 0.68 £20,639
OS by trial arm instead of PrePS and PPS £15,536 0.73 £21,357
Primary IRC assessment of PFS £16,009 0.65 £21,369
Investigator assessment of PFS £16,586 0.91 £18,737
Patients clinically ineligible for HSCT only £16,257 0.79 £20,195
All utilities based on Doorduijn 2005 [34] £16,212 0.75 £28,419
Using utility decrement for progressing based on Doorduijn 2005 [34] £16,212 0.69 £23,409
  1. Abbreviations: HSCT hematopoietic stem cell transplantation, ICER incremental cost-effectiveness ratio, IRC independent review committee, OS overall survival, PFS progression-free survival, PPS post-progression survival, PrePS pre-progression survival, QALY quality-adjusted life year